From the Guidelines
Myrbetriq (Mirabegron) is used to treat overactive bladder symptoms, including urinary frequency, urgency, and incontinence, in men with lower urinary tract symptoms (LUTS).
Key Points
- Mirabegron is a beta-3 adrenoceptor agonist that improves symptoms of overactive bladder, including frequency, urgency, and urgency urinary incontinence (UUI) 1.
- It can be used as monotherapy or in combination with alpha-1 adrenoceptor antagonists, such as tamsulosin, for the treatment of LUTS in men 1.
- Mirabegron is well tolerated in the elderly and in patients with multiple comorbidities, but it is contraindicated in patients with severe uncontrolled hypertension 1.
- The most frequent adverse events (AEs) associated with mirabegron are hypertension, urinary tract infections (UTIs), headache, and nasopharyngitis 1.
- Long-term data on the efficacy and safety of mirabegron in men with LUTS are limited, but available studies suggest that it is effective and well tolerated for up to 1 year 1.
Clinical Use
- Mirabegron can be used to treat men with LUTS who have overactive bladder symptoms, including those with benign prostatic hyperplasia (BPH) 1.
- The recommended dose of mirabegron is 25-50 mg once daily, and it can be taken with or without food 1.
- Mirabegron is not recommended for use in patients with severe renal impairment or end-stage renal disease, and it should be used with caution in patients with moderate renal impairment 1.
From the FDA Drug Label
Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
The use of Myrbetriq (Mirabegron) is for the treatment of:
- Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency
- Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more 2
From the Research
Use of Myrbetriq (Mirabegron)
- Myrbetriq (Mirabegron) is used to treat overactive bladder (OAB) symptoms, including urge urinary incontinence, urgency, and urinary frequency 3, 4, 5.
- It is a beta-3 adrenergic agonist, which works differently from antimuscarinic agents 3, 4, 6, 5.
- Mirabegron has been shown to be effective in reducing micturition frequency, urgency incontinence, and urgency, and improving health-related quality of life 3, 4, 6.
Efficacy and Tolerability
- Mirabegron has been compared to antimuscarinic monotherapies and combination therapies in several studies, and has been found to have similar efficacy and better tolerability in terms of dry mouth, constipation, and urinary retention 6.
- The drug has a good safety profile and causes no side effects typical of anticholinergics, such as dry mouth 3, 5.
- However, mirabegron may cause other adverse effects, including cardiac disorders, kidney stones, and skin reactions 7.
Patient Population
- Mirabegron is indicated for use in adults with OAB, including those who have previously been treated with antimuscarinics 4, 5.
- The drug may be a valuable treatment option for patients who have discontinued antimuscarinic therapy due to side effects such as dry mouth 3.
- However, the use of mirabegron in pregnant women is not recommended due to the lack of clinical data and potential risks 7.